MannKind Leans Into Growth Amid Earnings Volatility

MannKind Corporation ((MNKD)) has held its Q1 earnings call. Read on for the main highlights of the call.

MannKind’s latest earnings call carried a cautiously optimistic tone as management balanced solid double‑digit revenue growth with a frank discussion of short‑term pressure on profits. Executives highlighted strong momentum from FURO6, rising royalties, and advancing pipeline assets, while acknowledging that seasonality, integration work, and heavier investment are weighing on near‑term earnings but are intended to set up a stronger second half.

Quarterly Revenue Growth

MannKind reported Q1 2026 revenue of $90.0 million, up 15% versus a year ago, underscoring the benefit of its more diversified portfolio. Growth was driven in part by the inclusion of FURO6 following the SC Pharma acquisition, helping shift the mix toward higher “owned” revenue even as some legacy manufacturing lines softened.

FURO6 Commercial Momentum

FURO6 delivered net sales of $15.5 million in Q1 and a record number of prescribers, with 75% of writers returning. Doses dispensed jumped 64% year over year and were nearly 60% higher through April compared with the same period in 2025, supporting management’s confidence in reaffirming full‑year FURO6 guidance of $110 million to $120 million.

Afrezza Performance and Pediatric Readiness

Afrezza posted global net sales of $15.3 million, up 3% year over year, modest growth that was tempered by strategic reallocations of marketing spend. The company completed buildout for an Afrezza pediatric launch ahead of a late‑May regulatory decision and emphasized the sizable opportunity across 38 million patients in its labeled indications, including roughly 360,000 young U.S. type 1 diabetics.

United Therapeutics Collaboration & Milestones

The expanded collaboration with United Therapeutics added another revenue stream, with MannKind receiving a $5.0 million upfront payment for advancing ralinepag DPI. Management outlined potential development milestones of up to $35 million, about $15 million of which they expect to capture over the next 12 months, plus a future 10% royalty on net sales if development succeeds.

Tyvaso DPI Manufacturing Durability

MannKind underscored the durability of its manufacturing business by confirming it is the sole producer of Tyvaso DPI under a supply agreement that includes minimum volume commitments. These contractual minimums provide a more predictable baseline for annual manufacturing revenue, partially offsetting the inherent quarter‑to‑quarter variability in production scheduling.

Royalties and Cash Generation

Royalties climbed 9% year over year in Q1 to $32.7 million, highlighting the leverage in MannKind’s partnered portfolio. Management signaled that this growing, high‑margin royalty stream is funding strategic priorities, including retiring debt and advancing the company’s pipeline without relying solely on dilutive capital raises.

SC Pharma Integration and Synergies

Roughly seven months after closing the SC Pharma deal, MannKind reported that integration is largely complete for most functions. Synergies have already exceeded the previously targeted $20 million annually, suggesting the acquisition is tracking ahead of expectations and helping support the broader buildout of the company’s commercial infrastructure.

Pipeline Progress: MNKD‑201

In its pipeline, MannKind is advancing MNKD‑201, a dry powder form of nintedanib for idiopathic pulmonary fibrosis. The first cohort of the Phase 1b trial completed enrollment with no discontinuations for cough or serious adverse events among the initial 12 patients, with top‑line data expected in Q3 2026 and global Phase 2 enrollment already underway to accelerate development.

Q1 Profitability Decline

Despite higher revenue, MannKind swung to a GAAP net loss of $16.6 million, or $0.05 per share, and a non‑GAAP net loss of $6.9 million, or $0.02 per share. This compares with profits a year ago and reflects heavier commercial spending and acquisition‑related costs, as management framed 2026 as a deliberate investment year rather than a margin‑maximizing period.

Seasonal and Operational Headwinds

Q1 revenue was also pressured by structural seasonality, particularly insurance deductible resets that dampen early‑year prescription trends. Transitional disruptions, including a reorganization of field teams and shifting marketing resources away from adult Afrezza, led to fewer fills and contributed to FURO6 doses per prescription being roughly 20% lower than in the prior quarter.

Manufacturing Revenue Variability

Collaboration services and manufacturing revenue fell to $23.5 million from $29.4 million in the prior year, highlighting the volatility of this segment. Management attributed the decline to production scheduling variability at the Danbury plant and cautioned that manufacturing revenue may fluctuate from period to period even as long‑term contracts remain intact.

Higher Commercial and R&D Spend

Operating expenses moved higher as MannKind funded two anticipated launches and expanded the SC Pharma commercial platform. Research and development also increased to support MNKD‑201 and related programs, reinforcing management’s message that 2026 spending is intentionally elevated to seed future growth rather than reflect structural inefficiency.

Access and Operational Friction for FURO6

FURO6’s ramp has not been without friction, as around 60% of patients currently require prior authorization, creating an access hurdle for prescribers. The company is working to streamline access while managing inventory and sampling carefully ahead of the ReadyFlow auto‑injector launch, which has temporarily limited product availability in some channels.

Formulation and Development Uncertainties

Management was candid that ralinepag DPI’s formulation still requires optimization, with pharmacokinetics and final human PK/PD profiles yet to be fully defined. While early data and prototype selection have boosted confidence, executives reminded investors that clinical and regulatory outcomes for this new DPI program are not guaranteed and could still evolve.

Field Reorganization Disruptions

The reorganization of sales teams, including transferring nephrology responsibilities, caused near‑term customer disruption in January and February. These moves temporarily slowed Afrezza growth and contributed to uneven performance early in 2026, though management believes the new structure will better support the expanded portfolio over the long term.

Outlook and Forward Guidance

Looking ahead, MannKind reaffirmed its 2026 FURO6 revenue target of $110 million to $120 million and highlighted strong leading indicators such as a record number of writers and 97% year‑over‑year growth in integrated delivery networks. Key milestones in the coming quarters include regulatory decisions for Afrezza pediatrics and FURO6 ReadyFlow, expected ralinepag DPI milestones of about $15 million over 12 months, Phase 1b data for MNKD‑201, and a shift in owned revenue from roughly 40% before the SC deal to more than 65% exiting 2026.

MannKind’s earnings call painted a picture of a company trading short‑term margin pressure for long‑term scale, leaning into launches, integration, and pipeline advancement. For investors, the story hinges on execution in the second half of 2026, when FURO6 ReadyFlow, Afrezza pediatrics, and pipeline milestones will test whether today’s investment‑heavy strategy can translate into sustainable revenue growth and improving profitability.